Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke (KPCXM18)

A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase Ⅱb Clinical Trial to Evaluate the Efficacy and Safety of the KPCXM18 Injection at Different Doses in The Treatment of Acute Ischemic Stroke

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.

Study Overview

• Status: Recruiting
• Conditions: Acute Ischemic Stroke
• Intervention / Treatment: Drug: The KPCXM18 injection; Drug: The KPCXM18 injection; Drug: Placebo

Detailed Description

Trial Objectives:

The primary objective is to evaluate the efficacy of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.

The secondary objective is to evaluate the safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke and based on the population pharmacokinetic analysis method, explore the PK characteristics of the KPCXM18 injection in patients with acute ischemic stroke, and provide a basis for the design of the phase III clinical study.

Trial Design:

This trial is a multicenter, randomized, double-blind, parallel, placebo-controlled design. The subjects will be randomly assigned to the low-dose group, the high-dose group, and the placebo group at a ratio of 1:1:1, with 100 subjects in each group, totaling 300 subjects. The treatment will be administered continuously for 12±2 days to explore the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.

• Study Type: Interventional
• Enrollment (Estimated): 300
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Duo Gao, bachelor; Phone Number: 0871-68319868-3052; Email: GAODUO5@kpc.com.cn

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China
      • Recruiting
      • Beijing Tiantan Hosptial，Capital Medical University
  • Guangdong
    • Shenzhen, Guangdong, China
      • Recruiting
      • Shenzhen Second People's Hospital
  • Hebei
    • Cangzhou, Hebei, China
      • Recruiting
      • Cangzhou Central Hospital
    • Hengshui, Hebei, China
      • Recruiting
      • Hengshui People's Hospital
  • Heilongjiang
    • Daqing, Heilongjiang, China
      • Recruiting
      • Da Qing Long Nan Hospital
    • Daqing, Heilongjiang, China
      • Recruiting
      • Daqing Oilfield General Hospital
  • Henan
    • Anyang, Henan, China
      • Recruiting
      • The People's Hospital of Anyang City
    • Nanyang, Henan, China
      • Recruiting
      • The First Affiliated Hospital of Nanyang Medical College
    • Nanyang, Henan, China
      • Recruiting
      • Nanyang Second General Hospital
    • Nanyang, Henan, China
      • Recruiting
      • Nanshi Hospital of Nanyang
  • Jiangsu
    • Xuzhou, Jiangsu, China
      • Recruiting
      • Xuzhou Central Hospital
  • Jilin
    • Meihekou, Jilin, China
      • Recruiting
      • Meihakou Central Hospital
  • Liaoning
    • Shenyang, Liaoning, China
      • Recruiting
      • The People's Hospital of Liaoning Province
    • Shenyang, Liaoning, China
      • Recruiting
      • Affiliated Central Hospital of Shenyang Medical College
    • Shenyang, Liaoning, China
      • Recruiting
      • The first people's hospital of Shenyang
  • Shaanxi
    • Xianyang, Shaanxi, China
      • Recruiting
      • Yan'an University Xianyang Hospital
  • Shandong
    • Linyi, Shandong, China
      • Recruiting
      • Linyi People's Hospital
    • Linyi, Shandong, China
      • Recruiting
      • First People's Hospital Of Tancheng
    • Tengzhou, Shandong, China
      • Recruiting
      • Tengzhou Central People's Hospital
  • Shanxi
    • Datong, Shanxi, China
      • Recruiting
      • Sinopharm Tongmei General Hospital
    • Linfen, Shanxi, China
      • Recruiting
      • Linfen Central Hospital
    • Linfen, Shanxi, China
      • Recruiting
      • Linfen People's Hospital
  • Zhejiang
    • Jiaxing, Zhejiang, China
      • Recruiting
      • Jiaxing Second Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 1. Age 18 to 80 years old (including 18 years old and 80 years old, based on the date of signing the informed consent form), male or female;
• 2.Diagnosed with acute ischemic stroke according to the " Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023 ";
• 3.During the screening process, it is required that the ischemic stroke should occur within 12 hours after the onset, and it is expected that the investigational drug can be started within 12 hours after the onset; note: The onset time is calculated from the time when the ischemic stroke symptoms appear, If the onset occurs during sleep, the time of onset should be considered as the last time the patient was observed to be normal;
• 4.Before intravenous thrombolysis, 6 points ≤ NIHSS score ≤ 24 points, and the sum of upper limb and lower limb score ≥2 points;
• 5.The patients who first attacked, or the patients who had a good prognosis after the last attacked , (mRS score was ≤1 before the onset of the disease );
• 6.The subject has received or plans to receive standard intravenous thrombolysis treatment after this onset;
• 7.The subject can understand and follow the research process and voluntarily signs the research informed consent form (the informed consent form is signed by the subject or the legal representative).

Exclusion Criteria:

• 1. Patients with intracranial hemorrhagic diseases confirmed by Imaging: hemorrhagic stroke, epidural hematoma, intracranial hematoma, subarachnoid hemorrhage, ventricular hemorrhage, Traumatic cerebral hemorrhage, etc;
• 2. Patients who have received or plan to receive endovascular interventional treatment (including endovascular mechanical thrombectomy, intravascular thrombus aspiration, arterial thrombolysis, angioplasty and stenting) or patients with arteriovenous bridging therapy after this onset;
• 3. Patients with disturbance of consciousness (NIHSS score Ia>1 point);
• 4. Patient has a history of intracranial hemorrhage before;
• 5. Patient who have a history of epilepsy or who experienced epileptic symptoms during a stroke;
• 6. The patient with other mental illness (such as severe mental disorders, dementia) and combined conditions such as limb movement disorders may influence their neurological function tests;
• 7. Patients with acute myocardial infarction, cardiac interventional therapy, or heart failure (grade III and IV according to NYHA) within the past 1 month;
• 8. Patients with malignant tumors, serious diseases of blood, digestion or other systems or diseases with bleeding tendencies (such as hemophilia, etc.), and the expected survival time is not more than 3 months;
• 9. Despite active antihypertensive therapy, hypertension remains uncontrolled: systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg;
• 10.Patients with severe liver function impairment, or ALT, AST > 2.0× ULN;
• 11.Patients with severe renal impairment, or serum creatinine > 1.5× ULN;
• 12.Patients who have used neuroprotective drugs (including Edaravone, Edaravone Dexborneol, Butylphthalide, Piracetam, Urinary Kallidinogenase, Ginkgolide, Ginkgo Diterpene Lactone, Safflower Extract and Aceglutamide Injection, etc.) after the onset of this illness;
• 13.Patients with severe allergies, hypersensitivity to at least two or more types of drugs, or known to be allergic to any ingredient or excipient of the investigational drug;
• 14.Patients with a history of major surgery within 1 month before screening;
• 15.Patients with a history of drug abuse within 3 month before screening;
• 16.Patients who participated in or are currently participating in other clinical trials within 3 month prior to this study;
• 17.Pregnancy, lactation. or patients who have a family plan within 3 months of the first dose and who are unwilling to use contraception;
• 18.The investigator considers that patients are not suitable for clinical trials.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: low-dose group （The KPCXM18 injection）; The KPCXM18 injection (60 mg BID)	Drug: The KPCXM18 injection; Intravenous infusion of 60 mg twice daily at intervals of 12±2 hours for 12±2 days.; Drug: The KPCXM18 injection; Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 12±2 days.
Experimental: high-dose group （The KPCXM18 injection）; The KPCXM18 injection (100 mg BID)	Drug: The KPCXM18 injection; Intravenous infusion of 60 mg twice daily at intervals of 12±2 hours for 12±2 days.; Drug: The KPCXM18 injection; Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 12±2 days.
Placebo Comparator: Placebo; Placebo of the KPCXM18 injection( BID )	Drug: Placebo; Intravenous infusion twice a day with an interval of 12±2 hours for 12±2 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Modified Rankin Scale (mRS), with scores of 0-1 at Day 90	Proportion of subjects with mRS score ≤ 1 at day 90 after administration	day 90

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Modified Rankin Scale (mRS), with scores of 0-1 at day 12±2 and 30	Proportion of subjects with mRS score ≤ 1 at day 12±2 and 30 after administration	days 12±2 and 30
Modified Rankin Scale (mRS), with scores of 0-2 at days 12±2, 30 and 90	Proportion of subjects with mRS score ≤ 2 at day 12±2, 30, 90 after administration	days 12±2, 30 and 90
MRS Shift analysis	MRS shift analysis at day 90 after administration	day 90
National Institute of Health stroke scale (NIHSS) on day 12±2	Proportion of subjects with NIHSS score ≤ 1 or with ≥4 point reduction from baseline at day 12±2 after administration	days 12±2
National Institute of Health stroke scale (NIHSS) on day 12±2	Change in NIHSS score from baseline at day 12±2 after administration	days 12±2
Barthel index (BI) at Day 90	Proportion of subjects with BI score ≥95 at day 90 after administration	days 90
Barthel index (BI) at Day 90	Proportion of subjects with BI score ≥75 at day 90 after administration	days 90

Collaborators and Investigators

• Sponsor: Kunming Pharmaceuticals, Inc.
• Investigators: Principal Investigator: Yongjun Wang, MD, Beijing Tiantan Hospital

Study record dates

Study Major Dates

• Study Start (Actual): November 22, 2025
• Primary Completion (Estimated): October 18, 2026
• Study Completion (Estimated): October 18, 2026

Study Registration Dates

• First Submitted: November 23, 2025
• First Submitted That Met QC Criteria: December 9, 2025
• First Posted (Actual): December 12, 2025

Study Record Updates

• Last Update Posted (Actual): December 12, 2025
• Last Update Submitted That Met QC Criteria: December 9, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Stroke; Ischemic Stroke
• Other Study ID Numbers: KPCXM18-C202; kyjtcrc (Registry Identifier: Duo Gao)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No